Catalent to sell its U.S. commercial packaging ops to VC group Frazier Healthcare

Global CMO Catalent Pharma Solutions will unload its U.S. commercial packaging operations and sell it to venture capital group Frazier Healthcare for an undisclosed fee, according to a Catalent release.

An undisclosed company within the Frazier Healthcare portfolio will acquire the divisions based in Philadelphia and Woodstock, IL, sometime within the next few months, according to Catalent. The deal does not include clinical supply services operations in Philadelphia, or the blow-fill-seal business in Woodstock.

The sale comes as Catalent tweaks its business strategy to focus on expanding its other branches, which include development solutions and advanced delivery technologies, clinical trial supplies, advanced blow-fill-seal aseptic delivery technology for respiratory, ophthalmic and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products, according to the Catalent release.

A Catalent spokesman declined to disclose the cost of the sale, while a phone call to Frazier Healthcare has yet to be returned.

- read the Catalent statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.